chemoprotectant

chemoprotectant

 
1. providing protection against the toxic effects of chemotherapy agents.
2. an agent that so acts.

chemoprotectant

/che·mo·pro·tec·tant/ (-pro-tek´tant) providing protection, or an agent providing protection, against the toxic effects of chemotherapeutic agents.

chemoprotectant

1 adj, providing protection against the toxic effects of chemotherapy agents.
2 n, an agent that so acts.
Mentioned in ?
References in periodicals archive ?
We are very pleased with the interim safety results presented at ASCO especially the conclusion, that, to date, STS as a chemoprotectant appears to have no adverse effect on the efficacy of cisplatin.
Sodium thiosulfate has been shown to be a useful chemoprotectant when used in conjunction with cisplatin.
Since broccoli has long been suspected to contain a chemoprotectant, they tested it first.
NOV-002 is a small molecule compound based on a proprietary formulation of oxidized glutathione that acts together with chemotherapy as a chemopotentiator and a chemoprotectant by regulating redox-sensitive cell signaling pathways.
In several preclinical studies, SPI has showed that its novel chemoprotectant drug product, a small molecule that mimics and induces Glutathione Peroxidase activity was critical in preventing ototoxicity while not interfering with the chemotherapy treatment.
NOV-002, the lead compound currently in Phase 3 development for lung cancer under an SPA and Fast Track, acts together with chemotherapy as a chemopotentiator and a chemoprotectant.
BHA was used as a positive control to prove a chemoprotectant in assorted animal models of specific carcinogenicity (Hocman, 1988; Iverson, 1995; Iverson, 1999).
The reported findings also support the concept that the dual actions of NOV-002 in cancer patients as both a chemopotentiator and a chemoprotectant may reflect similar redox modulation in tumor and myeloid cells that results in opposite proliferative responses.
Expansion of the Company's oncology development pipeline through the in-license of BGP-15, a small molecule compound that has shown potential chemoprotectant properties in preclinical studies, and PDX, a novel, proprietary anti-folate (DHFR inhibitor), that has shown significant single-agent activity in a 39-patient Phase 2 trial in previously treated patients with non-small cell lung cancer.
BGP-15 is an orally bioavailable small molecule that has shown promise as a chemoprotectant in preclinical studies.
Now, combining N-Gene's science with Allos' expertise in clinical development and regulatory affairs, we see an increased opportunity to bring our new chemoprotectant drug to the market," said Gabor Kalman, Chairman and Chief Executive Officer of N-Gene.